Why do immune cells that are supposed to eliminate viruses suddenly turn against our own body? There are instances where ...
Nurix Therapeutics (NRIX) announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class ...
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9thBOSTON and ...
The poster, titled Translational Insights from a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors, expands upon data presented at the recent European Society for Medical ...
All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting® 2025 of AASLDAdditional preclinical data ...
PANoptosis, an emerging concept in immunology, refers to a form of programmed cell death that integrates various signaling ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data ...
Cell-based therapies have become integral to the routine clinical management of hematologic malignancies. Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in immunogenic solid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback